Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 227

1.

The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome.

Szymaszkiewicz A, Malkiewicz A, Storr M, Fichna J, Zielinska M.

J Physiol Pharmacol. 2019 Feb;70(1). doi: 10.26402/jpp.2019.1.01. Epub 2019 Apr 20.

PMID:
31019119
2.

[Patient perception and approval of fecal microbiota transplantation (FMT) as an alternative treatment option for ulcerative colitis].

Roggenbrod S, Schuler C, Haller B, Sohn M, Storr M, Schepp W, Gundling F.

Z Gastroenterol. 2019 Mar;57(3):296-303. doi: 10.1055/a-0821-7166. Epub 2019 Mar 12. German.

PMID:
30861553
3.

Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.

Szymaszkiewicz A, Storr M, Fichna J, Zielinska M.

Neurogastroenterol Motil. 2019 Apr;31(4):e13526. doi: 10.1111/nmo.13526. Epub 2018 Dec 14. Review.

PMID:
30549162
4.

Reizdarmtherapie ohne Medikamente.

Storr M.

MMW Fortschr Med. 2018 Dec;160(21-22):36. doi: 10.1007/s15006-018-1226-1. German. No abstract available.

PMID:
30542869
5.

[Interpretation und performance of high-resolution esophageal manometry: Recommendations of the German Association of Neurogastroenterology and Motility (DGNM) and the German Association of Gastroenterology, Digestive and Metabolic Diseases (DGVS)].

Keller J, Fox MR, Allescher HD, Frieling T, Fuchs KH, Goebel-Stengel M, Pehl C, Schirra J, van der Voort I, Storr M.

Z Gastroenterol. 2018 Nov;56(11):1378-1408. doi: 10.1055/a-0713-0944. Epub 2018 Nov 12. German.

PMID:
30419581
6.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17.

PMID:
30121173
7.

[Psychosomatics in gastroenterology - statement of the Work Group for Psychosomatics in Gastroenterology of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS)].

Auer PG, Enck P, Häuser W, Stengel A, Storr M, Langhorst J; AG Psychosomatik in der Gastroenterologie der DGVS.

Z Gastroenterol. 2018 Jun;56(6):684-689. doi: 10.1055/a-0599-1248. Epub 2018 Jun 11. German.

PMID:
29890563
8.
9.

Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice.

Szymaszkiewicz A, Zielinska M, Li K, Ramanathan M, Alam S, Hou DR, Fichna J, Storr M.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Apr;391(4):435-444. doi: 10.1007/s00210-018-1465-9. Epub 2018 Feb 5.

PMID:
29404698
10.

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.

Binienda A, Storr M, Fichna J, Salaga M.

Curr Drug Targets. 2018;19(15):1774-1781. doi: 10.2174/1389450119666171227225408.

PMID:
29284389
11.

FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.

Mosińska P, Jacenik D, Sałaga M, Wasilewski A, Cygankiewicz A, Sibaev A, Mokrowiecka A, Małecka-Panas E, Pintelon I, Storr M, Timmermans JP, Krajewska WM, Fichna J.

Neurogastroenterol Motil. 2018 May;30(5):e13272. doi: 10.1111/nmo.13272. Epub 2017 Dec 20.

PMID:
29266569
12.

[Four reasons for the bloated abdomen of your patient].

Storr M, Waggershauser C.

MMW Fortschr Med. 2017 Nov;159(20):43-48. doi: 10.1007/s15006-017-9601-x. German. No abstract available.

PMID:
29159608
13.

[Eosinophilic Esophagitis Update: New Guidelines of the European Study Group EUREOS].

Miehlke S, Schlag C, Storr M, Arnim UV.

Z Gastroenterol. 2018 Feb;56(2):139-150. doi: 10.1055/s-0043-121349. Epub 2017 Nov 9. German.

PMID:
29121691
14.

Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast.

Abdel-Aziz H, Kelber O, Lorkowski G, Storr M.

Planta Med. 2017 Oct;83(14-15):1130-1140. doi: 10.1055/s-0043-116852. Epub 2017 Aug 31. Review.

15.

Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Salaga M, Zatorski H, Zielińska M, Mosinska P, Timmermans JP, Kordek R, Storr M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1015-1027. doi: 10.1007/s00210-017-1402-3. Epub 2017 Jul 14.

PMID:
28710683
16.

Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT).

Bashashati M, Fichna J, Piscitelli F, Capasso R, Izzo AA, Sibaev A, Timmermans JP, Cenac N, Vergnolle N, Di Marzo V, Storr M.

Neurogastroenterol Motil. 2017 Dec;29(12). doi: 10.1111/nmo.13148. Epub 2017 Jul 11.

PMID:
28695708
17.

Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal.

Fabisiak A, Włodarczyk J, Fabisiak N, Storr M, Fichna J.

J Neurogastroenterol Motil. 2017 Jul 30;23(3):341-348. doi: 10.5056/jnm16203. Review.

18.

Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults.

Lucendo AJ, Molina-Infante J, Arias Á, von Arnim U, Bredenoord AJ, Bussmann C, Amil Dias J, Bove M, González-Cervera J, Larsson H, Miehlke S, Papadopoulou A, Rodríguez-Sánchez J, Ravelli A, Ronkainen J, Santander C, Schoepfer AM, Storr MA, Terreehorst I, Straumann A, Attwood SE.

United European Gastroenterol J. 2017 Apr;5(3):335-358. doi: 10.1177/2050640616689525. Epub 2017 Jan 23. Review.

19.

Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.

Madisch A, Vinson BR, Abdel-Aziz H, Kelber O, Nieber K, Kraft K, Storr M.

Wien Med Wochenschr. 2017 May;167(7-8):160-168. doi: 10.1007/s10354-017-0557-3. Epub 2017 Apr 19. Review.

20.

[Current treatment of dyspepsia in primary care].

Waggershauser CH, Allescher HD, Storr M.

MMW Fortschr Med. 2017 Apr;159(7):46-54. doi: 10.1007/s15006-017-9044-4. German. No abstract available.

PMID:
28417420

Supplemental Content

Loading ...
Support Center